Is the regression of atherosclerosis only possible by lowering LDL levels and is this sufficient to reduce the tendency of these lipoproteins to oxidative modification?;Czy regresja zmian miażdżycowych jest możliwa tylko przez obniżanie stȩżenia LDL i czy jest to działanie wystarczaja̧ce, by zredukowaç skłonność tych lipoprotein do oksydacyjnej modyfikacji?

Kardiologia Polska

Volumn 69, Issue 8, 2011, Pages 834-837

  Burchardt, Paweł ^a   Zurawski, Jakub ^a   Kubacki, Tomasz ^a   Wysocki, Henryk ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

apoB100; LDL oxidative modification

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; PROTEIN HOMEOSTASIS; REVIEW;

EID: 80051865305     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Ridker P.M., Danielson E., Fonseca F.A. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet, 2009; 373: 1175-1182.
2. Clearfield M. Statins in combinations: from ARBITER-6 HALTS to ACCORD - what works? Curr Atheroscl Rep, DOI: 10.1007/ /s11883-010-0142-3.
3. Alipour A., Van Oostrom A.J., Izraeljan A. et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol, 2008; 28: 792-797. (Pubitemid 351651339)
4. Steinbrecher U.P. Oxidation of human low densitylipoprotein results in derivatization oflysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem, 1987; 262: 3603-3608. (Pubitemid 17132923)
5. Parthasarathy S., Steinbrecher U.P., Barnett J., Witztum J.L., Steinberg D. Essential role of phospholipase A2 activity inendothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci USA, 1985; 82: 3000-3004. (Pubitemid 15097780)
6. Burchardt P., Wiktorowicz K., Goździcka-Józefiak A., Parucki R., Wysocki H. Disturbances in mitochondrial biosynthesis of acetyl-CoA and their role in the prevention of ischemic heart disease. Kardiol Pol, 2008; 66: 1215-1220.
7. Graham I. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis, 2007; 194: 1-45. (Pubitemid 47470068)
8. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest, 1991; 88: 1785-1792.
9. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet, 1994; 344: 793-795. (Pubitemid 24283962)
10. Mertens A., Hobvoet P. Oxidized and HDL: Antagonists in atherothrombosis. FASEB J, 2001; 15: 2073-2084.
11. Holvoet P., Stassen, J.M., Van Cleemput J., Collen D., Vanhaecke J. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol, 1998; 18: 100-107. (Pubitemid 28047605)
12. Holvoet P., Vanhaecke J., Janssens S., Van de Werf F., Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation, 1998; 98: 1487-1494. (Pubitemid 28481664)
13. Lee C., Sigari F., Segrado T. et al. All apoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified: Modulation of lipoprotein bioactivity by platelet- activating factor acetylhydrolase. Arterioscler Thromb Vasc Biol, 1999; 19: 1437-1446 (Pubitemid 29263013)
14. Steinbrecher U.P., Witztum J.L. Glucosylation of low density lipoproteins to an extent comparable to that seen in diabetesslows their catabolism. Diabetes, 1984; 33: 130-134. (Pubitemid 14184698)
15. Goldstein J.L., Ho Y.K., Basu S.K., Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA, 1979; 76: 333-337. (Pubitemid 9110191)
16. Fogelman A.M., Shechter I., Seager J., Hokom M., Child J.S., Edwards P. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA, 1980; 77: 2214-2218. (Pubitemid 10089629)
17. Brown M.S., Basu S.K., Falck J.R., Ho Y.K., Goldstein J.L. The scavenger cell pathway for lipoprotein degradation: Specificity of the binding site that mediates the uptake of negatively-charged LDL by macrophages. J Supramol Struct, 1980; 13: 67-81. (Pubitemid 11160139)
18. Ramos P., Gieseg S.P., Schuster B., Esterbauer H. Effect of temperature and phase transition on oxidation resistance of low density lipoprotein. J Lipid Res, 1995; 36: 2113-2128.
19. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest, 1998; 101: 1581-1590. (Pubitemid 28198486)
20. Vohl M.C., Neville T.A., Kumarathasan R., Braschi S., Sparks D.L. A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation ofoxidized lipids during lipoprotein oxidation. Biochemistry, 1999; 38: 5976-5981.
21. Ibanez B., Vilahur G., Cimmino G. et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: Magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol, 2008; 51: 1104-1109. (Pubitemid 351374767)
22. Nissen S.E., Tsunoda T., Tuzcu E.M. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA, 2003; 290: 2292-2300. (Pubitemid 37430562)
23. Min J.H., Jain M.K., Wilder C. et al. Membrane-bound plasma platelet activating factor acetylhydrolase acts on substrate in the aqueous phase. Biochemistry, 1999; 38: 12935-12942.
24. Kume N., Cybulsky M.I., Gimbrone M.A. Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest, 1992; 90: 1138-1144.
25. Macphee C.H. Lipoprotein-associated phospholipase A2: A potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol, 2001; 1: 121-125. (Pubitemid 33586401)
26. Arakawa H., Qian J-Y, Baatar D. et al. Local expression of platelet- activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits. Circulation, 2005; 111: 3302-3309. (Pubitemid 40875004)
27. Bui Q.T., Wilensky R.L. Darapladib. Exp Opin Investig Drugs, 2010; 19: 161-168.
28. Mohler III E.R., Ballantyne C.M., Davidson M.H. et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent. The results of a multicenter, randomized, double- blind, placebo-controlled study. J Am Coll Cardiol, 2008; 51: 1632-1641. (Pubitemid 351635837)
29. Kujiraoka T., Iwasaki T., Ishihara M. et al. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res, 2003; 44: 2006-2014. (Pubitemid 37356674)
30. Lamarche B., Moorjani S., Lupien P.J. et al. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation, 1996; 94: 273-278. (Pubitemid 26266109)
31. Talmud P.J., Hawe E., Miller G.J., Humphries S.E. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol, 2002; 22: 1918-1923. (Pubitemid 35315782)
32. Rader D.J., Hoeg J.M., Brewer H.B. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med, 1994; 20: 1012-1025. (Pubitemid 24169282)
33. Walldius G., Jungner I. The apoB/apoA-I ratio: A strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Int Med, 2006; 259: 493-519.
34. Su W., Campos H., Judge H., Walsh B.W., Sachs F.M. Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: Effect of postmenopausal estrogen replacement. J Clin Endocrinol Metab, 1998; 83: 3267-3276. (Pubitemid 28500971)